Compare RANI & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | NNOX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 69.6M |
| IPO Year | 2021 | 2019 |
| Metric | RANI | NNOX |
|---|---|---|
| Price | $0.54 | $0.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.20 | $4.13 |
| AVG Volume (30 Days) | 495.4K | ★ 830.3K |
| Earning Date | 11-17-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,633,000.00 | N/A |
| Revenue This Year | $283.19 | $71.03 |
| Revenue Next Year | $5.99 | $86.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.55 | $0.28 |
| 52 Week High | $2.16 | $4.71 |
| Indicator | RANI | NNOX |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 17.21 |
| Support Level | N/A | N/A |
| Resistance Level | $0.85 | $1.18 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 17.67 | 12.68 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.